Loading
companiesCompany
Blank Bio
Blank Bio trains AI models on tumour RNA to predict how a disease will progress and which patients will respond, so drug companies can run smarter cancer trials.
Overview
Blank Bio is an applied AI research lab training RNA foundation models on transcriptomic data to learn patterns of disease progression and treatment response, with the aim of improving clinical trial success rates in oncology by capturing what makes each patient's tumour unique. The team comes from Recursion, Deep Genomics, DeepMind, Amazon, Memorial Sloan Kettering, Stanford and the Vector Institute. Its website describes the work as RNA intelligence for precision oncology; products are in development.
Headquarters
San Francisco, CA, US
Funding
All startupsStartupYC S25
Investors
Type
Stage
Startup · Y Combinator Summer 2025
Website
Similar pages
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanySerinus Biosciences
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyArpeggio Bio
Shares Y Combinator, AI-driven drug & target discovery, RNA sequencing & expression profiling and the tag yc.
- CompanyHarmonic Discovery
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyOncobox
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyAlgen Biotechnologies
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyReverie Labs
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyData Driven Bioscience (Duoseq)
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.